Company intelligence / Profile preview

Bioceres

Rosario, Santa Fe, Argentina

Ownership: Private
Employees: ~389
Development stage: Other

Overview

Bioceres’ HB4 platform enables drought-tolerant crops, particularly soybeans and wheat, which have gained regulatory approvals and market uptake in multiple countries. The company’s biotech and microbial inputs have supported higher crop yields and resilience to climate stresses, with commercial validation.

Therapeutic areas: OtherInfectious Diseases
Modalities: BiologicMicrobial therapySeed trait genetic engineeringSmall molecule (crop protection)
Industry: Agriculture & AgTech

Partnerships

Bayer (Monsanto, strategic/corporate investor)joint ventures with leading seed companiespartnerships with government research agency CONICET

Beyond the preview

Go deeper on Bioceres.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioceres.

Explore the full profile